Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To review and analyse the evidence for the cholesterol-lowering effect of ezetimibe in adult patients with hypercholesterolaemia who are not at low-density lipoprotein cholesterol (LDL-C) goal on statin monotherapy. RESEARCH DESIGN: Systematic review and meta-analysis. METHODS: MEDLINE and EMBASE were searched to identify ezetimibe randomised controlled trials (RCTs) published between January 1993 and December 2005. The meta-analysis combined data from RCTs, with a minimum treatment duration of 6 weeks, that compared treatment with ezetimibe 10 mg/day or placebo added to current statin therapy. The difference between treatments was analysed for four co-primary outcomes: mean percentage change from baseline in total cholesterol (TC), LDL-C, and high-density lipoprotein cholesterol (HDL-C), and number of patients achieving LDL-C treatment goal. Meta-analysis results are presented for a modified version of the inverse variance random effects model. RESULTS: Five RCTs involving a total of 5039 patients were included in the meta-analysis. The weighted mean difference (WMD) between treatments significantly favoured the ezetimibe/statin combination over placebo/statin for TC (-16.1% (-17.3, -14.8); p < 0.0001), LDL-C (-23.6% (-25.6, -21.7); p < 0.0001) and HDL-C (1.7% (0.9, 2.5); p < 0.0001). The relative risk of reaching the LDL-C treatment goal was significantly higher for patients on ezetimibe/statin relative to those on placebo/statin (3.4 (2.0, 5.6); p < 0.0001). In pre-defined sub-group analyses of studies in patients with coronary heart disease, the WMD between treatments remained significantly in favour of ezetimibe/statin (p < 0.0001) for TC and LDL-C but was no longer significant for HDL-C. Elevations in creatine kinase, alanine aminotransferase or aspartate aminotransferase that were considered as an adverse effect did not differ significantly between treatments. CONCLUSIONS: The meta-analysis we performed included only five studies and was restricted to analysis of the changes in cholesterol levels relative to baseline. However, the results suggest that ezetimibe co-administered with ongoing statin therapy provides significant additional lipid-lowering in patients not at LDL-C goal on statin therapy alone, allowing more patients to reach their LDL-C goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Ballantyne, C. M., Blazing, M. A., King, T. R., Brady, W. E., & Palmisano, J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.060 · Cited by 202
Self-citationKosoglou, T., Meyer, I., Veltri, E. P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S. E., Patrick, J. E., Cutler, D. L., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01633.x · Cited by 117
Cited by
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
“Although BAS and CAI are both effective as monotherapy, the greater benefits are obtained when used in combination with statins, an effect that may be due to their complementary mechanism of actions [194].”
BackgroundRetracted2016 Chinese guidelines for the management of dyslipidemia in adults.
(2018) · PubMed · doi:10.11909/j.issn.1671-5411.2018.01.011 · Cited by 457
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 354
Metadata
- Authors
- Mikhailidis, D. P., Sibbring, G. C., Ballantyne, C. M., Davies, G. M., & Catapano, A. L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2007-07-19
- Volume
- 23
- Issue
- 8
- Pages
- 2009-2026
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2145866410
- Cited by
- 146
- References
- 5
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. https://app.cochat.ai/papers/10.1185/030079907x210507
- The paper
- Mikhailidis, D. P., Sibbring, G. C., Ballantyne, C. M., Davies, G. M., & Catapano, A. L. (2007). Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion. https://doi.org/10.1185/030079907x210507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.